Tango Therapeutics, Inc. has reported its financial performance for the fiscal year ending December 31, 2025, revealing a total revenue of $62.4 million, a significant increase from $30.0 million in 2024. This growth is attributed primarily to the recognition of all deferred revenue from its collaboration agreement with Gilead Sciences, which was truncated in August 2025. The company has not yet generated revenue from product sales, as it has no products approved for commercial sale, and it anticipates continued operating losses, with a net loss of $101.6 million for 2025 compared to $130.3 million in the previous year.
In terms of operational developments, Tango Therapeutics is focused on advancing its clinical pipeline, which includes two selective PRMT5 inhibitors, vopimetostat (TNG462) and TNG456, aimed at treating genetically defined cancers. The company reported positive data from ongoing Phase 1/2 clinical trials, including a median progression-free survival (mPFS) of 7.2 months in patients with MTAP-deleted pancreatic cancer. The company is also evaluating the combination of vopimetostat with RAS inhibitors, with early efficacy data showing promise. As of December 31, 2025, Tango had 137 full-time employees, with plans to expand its workforce to support ongoing and future clinical trials.
Tango Therapeutics has incurred significant net losses since its inception, with an accumulated deficit of $603.2 million as of the end of 2025. The company expects to continue incurring losses as it advances its product candidates through clinical development and seeks regulatory approvals. The company’s cash, cash equivalents, and marketable securities totaled $343.1 million, which it believes will fund operations into 2028. However, it will need to raise substantial additional funding to support its ongoing operations and development efforts.
The company faces numerous risks, including the need for substantial additional funding, potential delays in clinical trials, and the challenges of obtaining regulatory approvals for its product candidates. Tango Therapeutics has emphasized the importance of its collaborations, particularly with Gilead, and the potential impact of regulatory changes on its business. The company is also subject to various risks associated with cybersecurity, intellectual property, and compliance with healthcare laws, which could adversely affect its operations and financial condition.
Looking ahead, Tango Therapeutics remains focused on its strategic goals, including advancing its clinical development programs and exploring additional collaborations to enhance its product pipeline. The company is committed to addressing the unmet medical needs of patients with genetically defined cancers and aims to leverage its innovative approach to precision oncology to achieve long-term growth and success.
About Tango Therapeutics, Inc.
Tango Therapeutics is a precision oncology company focused on developing targeted cancer therapies by exploiting genetic vulnerabilities such as tumor suppressor gene loss. Its pipeline includes novel small molecules targeting PRMT5 and CoREST, aimed at genetically defined patient populations. The company leverages advanced target discovery platforms, collaborates with industry partners, and relies on third-party manufacturing to deliver innovative treatments for cancers with high unmet medical needs.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.